Today in Medicine: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Medicine.

Press releases published on April 20, 2026

Apr. 20, 2026

Soleo Health Expands Rare Disease Capabilities With Launch of SoleoRare™, A Specialty Pharmacy Focused on Complex Patient Needs

Indeterminate GlobeNewswire

Apr. 20, 2026

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Indeterminate GlobeNewswire

Apr. 20, 2026

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Indeterminate GlobeNewswire

Apr. 20, 2026

Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development

Indeterminate GlobeNewswire

Apr. 20, 2026

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

Indeterminate GlobeNewswire

Apr. 20, 2026

NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality

Indeterminate GlobeNewswire

Apr. 20, 2026

Conavi Medical Announces FDA 510(k) Clearance of its Next-Generation Hybrid IVUS-OCT System for Intravascular Imaging

Indeterminate GlobeNewswire

Apr. 20, 2026

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Indeterminate GlobeNewswire

Apr. 20, 2026

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

Indeterminate GlobeNewswire

Apr. 20, 2026

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

Indeterminate GlobeNewswire

Apr. 20, 2026

Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics

Indeterminate GlobeNewswire

Apr. 20, 2026

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

Indeterminate GlobeNewswire

Apr. 20, 2026

KFSH Joins C3 Davos of Healthcare™ 2026 in Sunnyvale, California, as a Global Strategic Partner

Indeterminate GlobeNewswire

Apr. 20, 2026

Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026

Indeterminate GlobeNewswire

Apr. 20, 2026

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

Indeterminate GlobeNewswire

Apr. 20, 2026

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

Indeterminate GlobeNewswire

Apr. 20, 2026

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Indeterminate GlobeNewswire

Apr. 20, 2026

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Indeterminate GlobeNewswire

Apr. 20, 2026

Nanobiotix annonce de nouvelles données précliniques démontrant une amélioration de la biodisponibilité systémique et la réduction de la toxicité pour des immunothérapies à ADN delivrées par LNP après traitement avec sa technologie de…

Indeterminate GlobeNewswire

Apr. 20, 2026

Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology

Indeterminate GlobeNewswire